Skip to main content


Johnson & Johnson Business Continuity Statement

Johnson & Johnson Business Continuity Statement
Working on a COVID-19 vaccine

In our role as a global health leader, Johnson & Johnson is closely monitoring the COVID-19 pandemic, caused by the coronavirus, and taking steps to help prevent the spread of the virus as well as exploring the potential for a vaccine.1

We have robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products. These steps include maintaining critical inventory at major distribution centres away from high-risk areas and working with external suppliers to support our preparedness plans.2

The need for increased restrictions in some countries to help address the spread of the virus is presenting global supply chains with unprecedented logistical challenges; however, we are working closely with suppliers, distributors, local governments and regulators to continue to meet patient, customer and consumer need. We are closely monitoring product demand and supply levels across our global network to ensure adequate and effective distribution and working to minimise delivery disruption to our customers who depend on us for timely delivery. We are also advising private and public customers to maintain normal ordering patterns where possible to avoid service delays, especially for those who rely on our critical medicines.


Back to COVID-19 Section


  1. Medical Countermeasures. Janssen Research and Development partner with BARDA to accelerate clinical trials and manufacturing of COVID-19 vaccine. Available at: Last accessed May 2020.
  2. Johnson & Johnson. Johnson & Johnson Business Continuity Statement (3/27). Available at: Last accessed: May 2020.